X
[{"orgOrder":0,"company":"Giiant pharma","sponsor":"Amplitude Ventures","pharmaFlowCategory":"D","amount":"$11.0 million","upfrontCash":"Undisclosed","newsHeadline":"Giiant Pharma inc Announced the Closing of US$11M in Seed Financing","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Giiant pharma"},{"orgOrder":0,"company":"Giiant pharma","sponsor":"Amplitude Ventures","pharmaFlowCategory":"D","amount":"$1.2 million","upfrontCash":"Undisclosed","newsHeadline":"Giiant Pharma inc Extended Its Seed Round With AQC Capital and CQDM to Ensure Reaching Clinical Proof-of-Concept","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Giiant pharma"},{"orgOrder":0,"company":"Giiant pharma","sponsor":"Palisade Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement with Giiant Pharma, Inc. for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"IND Enabling","country":"CANADA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Giiant pharma"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
Under the agreement, Palisade wil develop, manufacture and commercialize Giiant’s proprietary targeted prodrug platform, including GT-2108, an orally administered, gut-restricted, colon-specific PDE4 inhibitor prodrug in development for patients affected by ulcerative colitis.
Lead Product(s):
GT-2108
Therapeutic Area: Gastroenterology
Product Name: GT-2108
Highest Development Status: IND Enabling
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Palisade Bio
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Licensing Agreement
September 06, 2023
Details:
Giiant Pharma already initiated its IND-enabling preclinical program with its lead candidate, GT-2108, for the treatment of moderate-to-severe ulcerative colitis. This additional financing will support the development of GT-2108 up to clinical Phase 1b completion.
Lead Product(s):
GT-2108
Therapeutic Area: Gastroenterology
Product Name: GT-2108
Highest Development Status: IND Enabling
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Amplitude Ventures
Deal Size: $1.2 million
Upfront Cash: Undisclosed
Deal Type: Financing
June 30, 2021
Details:
The Company has identified GT-2108 as a lead candidate for the treatment of inflammatory bowel diseases (IBD). GT-2108 is an orally-administered, colon-specific PDE4 inhibitor prodrug with potent anti-inflammatory properties.
Lead Product(s):
GT-2108
Therapeutic Area: Gastroenterology
Product Name: GT-2108
Highest Development Status: IND Enabling
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Amplitude Ventures
Deal Size: $11.0 million
Upfront Cash: Undisclosed
Deal Type: Financing
May 19, 2021